"Technetium-99m pyrophosphate (Tc-99m PYP) is one of the technetium radiopharmaceuticals used primarily in the imaging diagnosis of transthyretin amyloidosis (ATTR) 1. It can also be used to detect abnormalities in the areas of calcium deposition and damaged tissues such as bone, blood and heart 2,3."
"physical half-life: ~6hours"
"dose: 99mTc-PYP: 370-640 MBq intravenously"
"uptake time 99mTc-PYP only: 1 hour"
"Technetium-99m is a metastable nuclear isomer with favourable gamma emission properties, thus it is frequently used in nuclear medicine."
"Transthyretin amyloidosis - Primary use 7:"
"Detection of acute myocardial infarction - historical use 2:"
"Bone imaging - historical use 3:"
"dose: 99mTc-PYP: 370-640 MBq intravenously"
"uptake time 99mTc-PYP only: 1 hour"
"CT attentuation correction: heart recommended. SPECT/CT fusion is helpful in localising tracer uptake to the myocardium"
"within 24- 72 hours post event"
"Technetium-99m is a metastable nuclear isomer with favourable gamma emission properties, thus it is frequently used in nuclear medicine."
"Pyrophosphate is a ligand containing two phosphate groups and a high affinity for calcium-rich environments. It is chelated to technetium-99m."
"Technetium-99m pyrophosphate (Tc-99m PYP) is one of the technetium radiopharmaceuticals used primarily in the imaging diagnosis of transthyretin amyloidosis (ATTR) 1. It can also be used to detect abnormalities in the areas of calcium deposition and damaged tissues such as bone, blood and heart 2,3."
"Technetium-99m pyrophosphate (Tc-99m PYP) is one of the technetium radiopharmaceuticals used primarily in the imaging diagnosis of transthyretin amyloidosis (ATTR) 1. It can also be used to detect abnormalities in the areas of calcium deposition and damaged tissues such as bone, blood and heart 2,3."
"it has a high affinity for extracellular amyloid deposits (i.e. those found in ATTR) 6"
"dose: 99mTc-PYP: 370-640 MBq intravenously"
"uptake time 99mTc-PYP only: 1 hour"
"Tc-99m PYP was first curated in the mid 1970s and was one of the first radiotracers used to image acute myocardial infarctions 2. With advances in medicine, it was replaced by more specific tests such as troponin. Tc-99m PYP was discovered to have a high affinity for transthyretin amyoid in mid-2000 resulting in the adoption for non-invasive diagnosis of ATTR 1."
"Tc-99m PYP was first curated in the mid 1970s and was one of the first radiotracers used to image acute myocardial infarctions 2. With advances in medicine, it was replaced by more specific tests such as troponin. Tc-99m PYP was discovered to have a high affinity for transthyretin amyoid in mid-2000 resulting in the adoption for non-invasive diagnosis of ATTR 1."
"Tc-99m PYP was first curated in the mid 1970s and was one of the first radiotracers used to image acute myocardial infarctions 2. With advances in medicine, it was replaced by more specific tests such as troponin. Tc-99m PYP was discovered to have a high affinity for transthyretin amyoid in mid-2000 resulting in the adoption for non-invasive diagnosis of ATTR 1."
"Transthyretin amyloidosis - Primary use 7:"
"Detection of acute myocardial infarction - historical use 2:"
"Bone imaging - historical use 3:"
"Technetium-99m is a metastable nuclear isomer with favourable gamma emission properties, thus it is frequently used in nuclear medicine."
"Technetium-99m is a metastable nuclear isomer with favourable gamma emission properties, thus it is frequently used in nuclear medicine."
Expected headings
"Characteristics"
"Uses, doses and timings"
"Technetium-99m pyrophosphate (Tc-99m PYP) is one of the technetium radiopharmaceuticals used primarily in the imaging diagnosis of transthyretin amyloidosis (ATTR) 1. It can also be used to detect abnormalities in the areas of calcium deposition and damaged tissues such as bone, blood and heart 2,3."
"Uses, doses and timings"
"increased tracer uptake in areas of increased osteogenesis or bone growth (e.g. fractures)"